Journal article
Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia
Leukemia & lymphoma, Vol.61(7), pp.1702-1708
06/06/2020
DOI: 10.1080/10428194.2020.1737687
PMCID: PMC9393046
PMID: 32157936
Abstract
Polypharmacy, usually defined as taking ≥5 prescribed medications, increases chances of drug-drug interactions and toxicities, and may harm cancer patients who need multiple chemotherapeutic agents and supportive medications. We analyzed the effects of polypharmacy in overall survival (OS) in acute myeloid leukemia (AML). A total of 399 patients were divided into two groups: patients with polypharmacy (≥5 medications) versus without polypharmacy (<5 medications). Polypharmacy was associated with age ≥60 years, Karnofsky Performance Status of ≤80, hematopoietic cell transplant (HCT) comorbidity index of ≥5, and adverse cytogenetics. Patients with polypharmacy were less likely to receive intensity chemotherapy or HCT. One-year OS of patients with polypharmacy versus those without polypharmacy was 29 vs. 49% (p<.001). Polypharmacy conferred worse OS in patients <60 years (37 vs. 65% at 1 year, HR 1.95, 95% CI 1.21-3.15) but not in patients ≥60 years (26 vs. 27% at 1 year, HR 1.12, 95% CI 0.81-1.57). Thus, polypharmacy has negative impact on OS in AML, particularly among patients aged <60 years.
Details
- Title: Subtitle
- Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia
- Creators
- Prajwal Dhakal - University of Nebraska Medical CenterElizabeth Lyden - University of Nebraska Medical CenterKate-Lynn E. Muir - University of Nebraska Medical CenterZaid S. Al-Kadhimi - University of Nebraska Medical CenterThuy Koll - University of Nebraska Medical CenterLori J. Maness - University of Nebraska Medical CenterKrishna Gundabolu - University of Nebraska Medical CenterVijaya Raj Bhatt - University of Nebraska Medical Center
- Resource Type
- Journal article
- Publication Details
- Leukemia & lymphoma, Vol.61(7), pp.1702-1708
- DOI
- 10.1080/10428194.2020.1737687
- PMID
- 32157936
- PMCID
- PMC9393046
- NLM abbreviation
- Leuk Lymphoma
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Publisher
- Taylor & Francis
- Grant note
- P30 CA036727 / National Cancer Institute National Institute of General Medical Sciences
- Language
- English
- Date published
- 06/06/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359778702771
Metrics
21 Record Views